Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.36 |
| ▸ | FASN | P49327 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | ADH1B | P00325 | 1/20 | 0.32 |
| ▸ | ADH1C | P00326 | 1/20 | 0.32 |
| ▸ | ADH1A | P07327 | 1/20 | 0.32 |
| ▸ | ADH7 | P40394 | 1/20 | 0.32 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.32 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7718147 | 0.83 | CTRB1 (0.33) | CTRB1FASNGRM2 | |
| SCHEMBL5220133 | 0.80 | HCAR2 (0.43) | — | |
| SCHEMBL6863242 | 0.77 | ADH1B (0.38) | CTRB1F2PRSS1FASNGRM2 | |
| SCHEMBL17512439 | 0.75 | CALM1 (0.39) | CTRB1F2PRSS1FASNGRM2 | |
| SCHEMBL7593855 | 0.74 | MAPT (0.40) | — | |
| SCHEMBL5858339 | 0.73 | CTRB1 (0.38) | CTRB1FASNGRM2TLR9 | |
| SCHEMBL3744743 | 0.73 | CTRB1 (0.35) | CTRB1F2PRSS1FASNGRM2 | |
| SCHEMBL5754991 | 0.73 | TAAR1 (0.39) | CTRB1FASNGRM2 | |
| SCHEMBL746094 | 0.73 | CTRB1 (0.35) | CTRB1FASNGRM2 | |
| SCHEMBL3972137 | 0.73 | CTRB1 (0.35) | CTRB1FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 302 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662434-B2 | Use of specific compounds for enhancing odours | SYMRISE AG (DE) | 2023-08-16 | — | — | EP | claimed |
| US-10920170-B2 | Fragrance mixtures containing tricyclo[5.2.1.0]-decane-8-ethyl ether | SYMRISE AG (DE) | 2021-02-16 | — | — | US | claimed |
| US-20200063063-A1 | FRAGRANCE MIXTURES CONTAINING TRICYCLO[5.2.1.0]-DECANE-8-ETHYL ETHER | SYMRISE AG (DE) | 2020-02-27 | — | — | US | claimed |
| EP-3601509-A1 | FRAGRANCE MIXTURES CONTAINING TRICYCLO[5.2.1.0]-DECANE-8-ETHYL ETHER | Symrise AG (DE) | 2020-02-05 | — | — | EP | claimed |
| EP-2662098-B1 | Use of specific compounds for changing odours | SYMRISE AG (DE) | 2018-10-24 | — | — | EP | claimed |
| WO-2018171872-A1 | FRAGRANCE MIXTURES CONTAINING TRICYCLO[5.2.1.0]-DECANE-8-ETHYL ETHER | SYMRISE AG (DE) | 2018-09-27 | — | — | WO | claimed |
| EP-2662434-B1 | Use of specific compounds for enhancing odours | SYMRISE AG (DE) | 2018-03-21 | — | — | EP | claimed |
| US-9340751-B2 | Use of specific compounds for modifying odors | SYMRISE AG (DE) | 2016-05-17 | — | — | US | claimed |
| US-20130303432-A1 | Use Of Specific Compounds For Modifying Odors | SYMRISE AG (DE) | 2013-11-14 | — | — | US | claimed |
| EP-2662434-A1 | Use of specific compounds for enhancing odours | Symrise AG (DE) | 2013-11-13 | — | — | EP | claimed |
| US-7226921-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-06-05 | — | — | US | claimed |
| US-7196099-B2 | Compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-27 | — | — | US | claimed |
| US-6977256-B2 | Compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-20 | — | — | US | claimed |
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. | 2004-09-30 | — | — | US | claimed |
| EP-1446392-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-08-18 | — | — | EP | claimed |
| EP-1436255-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | Aventis Pharmaceuticals, Inc. (US) | 2004-07-14 | — | — | EP | claimed |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | AXYS PHARMACEUTICALS INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003042197-A1 | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM AS CATHEPSIN S INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-05-22 | — | — | WO | claimed |
| WO-2003024924-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS CATHEPSIN INHIBITORS | AVENTIS PHARMACEUTICALS INC. (US) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267044-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | CTRB1 26/4885F2 3562/4885PRSS1 19/4885 |
| US-10920170-B2 | Fragrance mixtures containing tricyclo[5.2.1.0]-decane-8-ethyl ether | CCT8, F8, TRPM8 | CTRB1 1413/4885F2 180/4885PRSS1 3526/4885 |
| US-20200063063-A1 | FRAGRANCE MIXTURES CONTAINING TRICYCLO[5.2.1.0]-DECANE-8-ETHYL ETHER | CCT8, F8, TRPM8 | CTRB1 1413/4885F2 180/4885PRSS1 3526/4885 |
| US-20040192742-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | CTRB1 24/4885F2 3329/4885PRSS1 29/4885 |
| US-20030199506-A1 | Novel compounds and compositions as cathepsin S inhibitors | CTSS, CTSB, CTSE | CTRB1 26/4885F2 3591/4885PRSS1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.